HealthTech Arkansas
VC Fund
Little Rock, United States
HealthTech Arkansas is an investment firm that targets three areas of healthcare innovation digital health, medical devices, and diagnostic platforms. The firm seeks technologies that can improve our providers’ operations by improving the quality of care, enhancing efficiencies, and reducing costs.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries HealthTech Arkansas invests in
Stages HealthTech Arkansas invests in
Countries HealthTech Arkansas invests in
Investment Focus
Industry
- Health Care 2 (67%)
- Medical Device 2 (67%)
- Medical 1 (33%)
- Software 1 (33%)
- Artificial Intelligence 1 (33%)
Stage
- Seed 1 (33%)
- Series A 1 (33%)
- Non-equity Assistance 1 (33%)
Country
- Sweden 1 (33%)
- South Korea 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Mediwhale
|
Medi Whale seeks to achieve sustainable healthcare where every eye can truly be the window to one’s health with our world's first-of-its-kind 1-stop AI screening platform solution for cardiovascular, renal, metabolic risk assessment, and eye disease diagnosis. Our AI Platform was developed through several clinical collaborations (Korea,Singapore, India, UK, and other European datasets) using structured longitudinal event-based datasets for the development of our retinal biomarker engines. RetiCVD® (cardiovascular disease risk assessment): Developed using coronary artery calcium (CAC) score, CAC is recognized as the gold standard for precise CVD risk calculation. Our CVD engine predicts the presence of CAC and provides a stratified probabilistic risk based on US ASCVD and EU SCORE guidelines.RetiCKD® (chronic kidney disease risk assessment): Developed using eGFR and full lab panel, our CKD engine has been demonstrated to achieve better predictive capability as compared to eGFR or full panel analysis.RetiEYE®: Referable Eye Disease engine detects and flags common aging-related eye modalities such as diabetic retinopathy, age-related macular degeneration, glaucoma, and cataract at its referable disease state.Medi Whale retinal-based systemic biomarkers have been clinically demonstrated to be non-inferior to current gold standards and are recognized by clinical and scientific communities with two Lancet Digital Health publications. | $9M / Series A / Apr 18, 2023 | |
Acorai
|
Acorai is developing a device for heart failure management through non-invasive intracardiac pressure monitoring (ICPM), to help reduce hospitalizations and readmissions. Our product, The Acorai Heart Monitor, can monitor mean pulmonary artery pressure (mPAP) non-invasively through a machine learning analysis of pressure dynamics in acoustics,vibratory and waveform data. Our technology show compelling precision, has a low-risk clinical and regulatory pathway, a low dependence on reimbursement and a fast track to commercialization. With a team with more than 50 years of industry experience, we can help heart failure patients live longer, healthier, and less uncertain lives.Acorai was founded in 2019 and is headquartered in Skane, Sweden. | Non-equity Assistance / Nov 24, 2022 | |
|
Acorai
|
Acorai is developing a device for heart failure management through non-invasive intracardiac pressure monitoring (ICPM), to help reduce hospitalizations and readmissions. Our product, The Acorai Heart Monitor, can monitor mean pulmonary artery pressure (mPAP) non-invasively through a machine learning analysis of pressure dynamics in acoustics,vibratory and waveform data. Our technology show compelling precision, has a low-risk clinical and regulatory pathway, a low dependence on reimbursement and a fast track to commercialization. With a team with more than 50 years of industry experience, we can help heart failure patients live longer, healthier, and less uncertain lives.Acorai was founded in 2019 and is headquartered in Skane, Sweden. | $1.5M / Seed / Apr 01, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does HealthTech Arkansas invest in?
HealthTech Arkansas invests primarily in Health Care, Medical Device and Medical startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did HealthTech Arkansas last invest?
The most recent investment recorded for HealthTech Arkansas closed in Apr 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
